Men and women between the ages of 18 & 65 with a diagnosis of ulcerative colitis may participate in a research study for an investigational drug, which has been developed as a potential therapy to reduce the inflammation and tissue damage associated with a colitis flare without suppressing the patient's immune system.
Interested candidates may enroll if they're currently experiencing the symptoms of a colitis flare.
The study drug is given through intravenous infusion and study participants may be given 1, 3, or 5 doses of the study drug depending on the severity of their symptoms. Study participants might also receive a placebo during the study rather than the active study drug.
Participation in the study will involve approximately 9 outpatient visits to the Duke Clinical Research Unit over the course of 10 to 14 weeks. Enrolled participants will receive financial compensation for their time.
For more information, please call the DCRU at 919-613-6246 or email us at email@example.com
For more information, contact Duke Clinical Research Unit at 919-613-6246.